AIQ Solutions

The company's core offering is the TRAQinform IQ software platform, a clinical decision support tool for oncologists, radiologists, and nuclear medicine specialists. This technology analyzes PET and CT scan images to automatically detect, segment, and quantify cancerous lesions body-wide. It provides a detailed report and 3D visualizations that map out how each individual tumor is responding to therapy over time, highlighting areas of progression, regression, or stability. This allows clinicians to move beyond assessing just a few sample lesions and gain a holistic view of the patient's total disease burden, enabling more personalized and timely adjustments to treatment plans. The software addresses the critical challenge of tumor heterogeneity, where different tumors in the same patient may have varied responses to treatment.

AIQ Solutions operates in the health-tech and oncology markets, serving hospital systems and pharmaceutical and biotech companies. For hospitals, the platform aids in real-time patient therapy management and has received FDA 510(k) clearance for clinical use with several cancer types, including lung, prostate, and lymphoma. The company aims for its technology to become a standard of care and is working towards securing insurance and Medicare reimbursement. For pharmaceutical clients, the technology is used in early-stage studies to better understand drug effects, toxicity risks, and mechanisms of resistance. The company has raised approximately $17.2 million from investors such as Capital Midwest Fund and Rock River Capital Partners, supplemented by nearly $2.7 million in grants from the National Cancer Institute.